Repligen RGEN
United StatesHealthcare · Medical Instruments & SuppliesUSD
194.95 USD (+16.6%)
20 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Repligen Corporation is a bioprocessing company that designs, manufactures, and sells products and solutions (chromatography, filtration, process control) used in the production of biologic drugs, from research to commercial manufacturing.
Key points
from its scores- ✓Very solid balance sheet7.3
- ✕Little or no dividend1.5
- ✕Demanding valuation1.7
- ✕Weak growth3.5
AI analysis
bottom line, main risk, context and newsHold only if you have confidence in a medium-term margin recovery; this is not the time to add a position given such an demanding valuation and sharply falling earnings.
Repligen shows solid financial health with net cash (DN/EBITDA -0.83) and high liquidity (9.05), but its profitability is very weak (ROE 1.99%, ROIC 2.38%) and the earnings decline (-65.9%) contrasts with 11.9% revenue growth. The valuation is extremely demanding (P/E 229, EV/EBITDA 64.66), leaving little room for error and making the price dependent on a margin and earnings recovery that is not yet visible.
The main risk is the combination of an extreme valuation (P/E 229, EV/EBITDA 64.66) with currently very low profitability (ROE 1.99%) and a 65.9% earnings decline, leaving the price highly exposed to any disappointment in the margin recovery.
Context and risks
No recent relevant news and no material exposure to current macro factors (rates, oil, tariffs). The bioprocessing business does not depend on commodities or conflict maritime routes, and its net cash balance sheet insulates it from the rise in rates.
Is Repligen stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 552% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 229.1 | 26.7 | +757% |
| EV / EBITDA | 64.7 | 14.5 | +347% |
| Price / book | 4.5 | 4.1 | +9% |
| Price / sales | 13.5 | 3.4 | +296% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.7 out of 10 (median for Healthcare: 4.7).
Average analyst target: 194.95 USD, +16.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 4.5 (sector 5.5), Growth 3.5 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 229.1
- Forward P/E
- 63.2
- EV / EBITDA
- 64.7
- Price / book
- 4.5
- Price / sales
- 13.5
- PEG
- 1.74
- Market cap
- 10.6B USD
- Enterprise value
- 9.3B USD
Profitability
- ROE
- 2.0%
- ROA
- 1.4%
- ROIC (approx.)
- 2.4%
- Gross margin
- 53.8%
- Operating margin
- 9.3%
- Net margin
- 5.3%
- Free cash flow
- 113.4M USD
- FCF yield
- 1.1%
- Cash conversion
- 79%
Solvency
- Total debt
- 690.9M USD
- Net debt
- −119.5M USD
- Cash
- 810.4M USD
- EBITDA
- 144.1M USD
- Net debt / EBITDA
- −0.83
- Debt / equity
- 32.72
- Current ratio
- 9.05
- Quick ratio
- 7.30
Growth
- Revenue growth
- +11.9%
- Earnings growth
- −65.9%
- EPS (TTM)
- 0.73 USD
- EPS (forward)
- 2.65 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.08
- Analyst consensus
- Strong buy (20)
- Target price
- 194.95 USD
- 52-week range
- 100.99 – 198.87
Recent news
All RGEN news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Repligen
Is Repligen stock cheap or expensive?
On P/E and EV / EBITDA, it trades 552% above the Healthcare median on average. Valuation score: 1.7 out of 10 (median for Healthcare: 4.7). Average analyst target: 194.95 USD, +16.6% versus the price. This is not investment advice.
What score does Repligen get on MeridIAn Screener?
It scores 4.4 out of 10, rank 1,908 of 2,130 (better than 10% of the companies analysed). Its strongest category is Financial health (7.3) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Repligen's P/E ratio?
Its P/E is 229.1: the share price equals 229.1 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 63.2.
How much is Repligen worth on the stock market?
Its market capitalisation is 10.6B USD and its enterprise value, debt included, is 9.3B USD.
How much debt does Repligen have?
It has more cash than debt: net cash of 119.5M USD.
Does Repligen pay a dividend?
It pays no dividend, or almost none.
How has Repligen stock performed over the last year?
It has risen 15.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 100.99 and 198.87 USD. Past performance does not guarantee future results.
What do analysts think of Repligen?
20 analysts cover it; their average recommendation is “Strong buy” and their average target is 194.95 USD (+16.6% versus the price). It is an estimate, not market data.